Sandoz’ Ziextenzo And Riximyo Cleared In Canada

Company Has Portfolio Of Five Biosimilars Planned For 2021

 
• By Dean Rudge

Sandoz Canada is looking to bolster its portfolio of biosimilars after obtaining marketing authorizations for both pegfilgrastim and rituximab.

CanadianFlags
Sandoz is eyeing a portfolio of five biosimilars in Canada • Source: Shutterstock

More from Biosimilars

More from Products